Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BHV-1530 · 1 trial · 1 indication
Incidence and severity of TEAEs, including DLTs, SAEs and change from baseline for laboratory values, electrocardiograms (ECGs), vital signs, and physical exams to determine the safety profile, MTD, MRAD and RDR of BHV-1530 monotherapy and in combination with cemiplimab.
Incidence and severity of treatment-emergent AEs and SAEs, changes between baseline and postbaseline in laboratory values, ECGs, vital signs, and physical exams.
| Arm | Type | Description |
|---|---|---|
| BHV-1530 Monotherapy | EXPERIMENTAL | - |
| Experimental: BHV-1530 in combination with Cemiplimab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BHV-1530 | DRUG | BHV-1530 will be administered as an IV infusion on Day 1 of each 21-day cycle |
| Cemiplimab | DRUG | cemiplimab (350 mg) will be administered as an IV infusion on Day 1 of each 21-day cycle |
Inclusion Criteria: 1. Signed, written Independent Ethics Committee (IEC)/Institutional Review Board (IRB)-approved informed consent 2. Age greater than or equal to 18 years 3. Participants consent to provide tumor tissue collected prior to study treatment, preferably from a biopsy performed after ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
BHV-1530 is an investigational small molecule being developed for the treatment of solid tumors. It is currently in Phase 1 clinical development as a potential therapy for advanced solid tumors. The drug is being studied in a clinical trial that is recruiting patients with solid tumors.
BHV-1530 targets FGFR3, a receptor in the fibroblast growth factor receptor family. By targeting FGFR3, the drug aims to interfere with signaling pathways that may drive tumor growth. This mechanism is being evaluated in the context of solid tumors, where FGFR3 alterations are sometimes present.
BHV-1530 is being developed by Biohaven Ltd., a biopharmaceutical company. The company is conducting a Phase 1 clinical trial of BHV-1530 in advanced solid tumors. Biohaven is listed on the stock exchange under the ticker symbol BHVN.
BHV-1530 is in Phase 1 clinical development. It is an investigational drug that has not yet been approved by regulatory authorities. The ongoing Phase 1 trial is designed to evaluate the drug in patients with advanced solid tumors, and it is currently recruiting participants.
BHV-1530 is being studied in a Phase 1 clinical trial with the identifier NCT06874335. The trial, titled 'A Phase 1 Study of BHV-1530 in Advanced Solid Tumors,' is recruiting patients in the United States. The study is a controlled trial with an estimated enrollment of 140 participants.